Strategic partnerships Candel has recently secured collaboration and financing activity with key players (EVERSANA for US commercialization, Batavia Biosciences for scalable CAN-3110 manufacturing, RTW Investments for royalty funding). This suggests a ready path for distribution, manufacturing support, and strategic capital partnerships that can be leveraged to accelerate co-commercialization and market access.

Clinical programs breadth Multiple pluripotent viral immunotherapy programs across HSV and adenovirus platforms are in Phase 2/3 or investigator-sponsored trials (CAN-3110 in HGG; CAN-2409 in NSCLC, pancreatic, and prostate cancers). This highlights opportunities to engage clinics and payers around a broad-pipeline narrative and potential expansion into additional solid tumors.

US market readiness Active steps toward US commercialization support with a formal agreement to partner for launch of CAN-2409 indicate readiness to mobilize a US market entry plan, including clinical development alignment, regulatory strategy, and payer engagement—area where a BD team can offer accelerated access and local market expertise.

Manufacturing scalability Partnership with Batavia Biosciences to develop scalable manufacturing for CAN-3110 signals a vendor-ready pathway for supply chain stability, capacity expansion, and potential cost-of-goods improvements—key selling points when engaging potential manufacturers, contract manufacturers, and strategic investors.

Financial growth signals Significant growth capital and royalty funding activity (Trinity Capital and RTW Investments) demonstrates investor confidence and potential for non-dilutive or low-dilution financing avenues, which can be appealing to strategic buyers, co-development partners, and emerging market access allies seeking favorable financing terms.